AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Should l Buy ATRC?
Source: Newsfilter
Landmark Clinical Trial: The LeAAPS trial, the largest cardiac surgery device trial with 6,500 patients enrolled, evaluates the AtriClip devices for stroke reduction in cardiac surgery patients without a preoperative Afib diagnosis.
Long-term Impact: Results from the trial are expected to influence clinical practices and treatment guidelines for stroke prevention, with a five-year follow-up planned to assess long-term outcomes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRC
Wall Street analysts forecast ATRC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.800
Low
45.00
Averages
52.20
High
64.00
Current: 31.800
Low
45.00
Averages
52.20
High
64.00
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AtriCure Shares Plunge After JPMorgan Downgrade
- Downgrade Impact: JPMorgan downgraded AtriCure from Overweight to Neutral, causing shares to plunge by 15% during mid-day trading on Wednesday, indicating market concerns about the company's future performance.
- Price Target Reduction: The brokerage lowered its price target for AtriCure from $48 to $36, reflecting a significant decrease in analysts' expectations for the company's profitability, which may undermine investor confidence.
- Increased Competitive Pressure: The announcement by Edwards Lifesciences to launch a surgical left atrial appendage closure product, which competes with AtriCure's AtriClip, intensifies market competition and poses a threat to AtriCure's market share.
- Changing Market Position: Edwards Lifesciences' leading position in the cardiac surgery market, particularly in surgical valve replacements, could weaken AtriCure's market position in its Open business, further impacting its long-term growth potential.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
See More
AtriCure Inc (ATRC) Releases 2025 Product Pipeline Analysis Report
- Product Pipeline Overview: AtriCure Inc's newly released 2025 Product Pipeline Analysis report provides key insights into its major products and brands, enhancing decision-making capabilities in the competitive medical technology market.
- Technical Expertise: AtriCure specializes in developing and providing medical devices for cardiac surgeries, including the Isolator Synergy ablation system and AtriClip left atrial appendage exclusion system, addressing the needs of electrophysiologists and cardiothoracic surgeons.
- Market Coverage: The company operates in multiple countries including the US, Germany, France, the UK, Canada, and Australia, showcasing its extensive global footprint aimed at enhancing competitiveness in the cardiac medical device sector.
- Brand Diversity: AtriCure markets its products through various brands such as Coolrail, Flex-V, and Hybrid AF, which increases the diversity of its product portfolio and enhances customer choice and market penetration.
See More
AtriCure (ATRC) Sees a 6.32% Increase Over the Past Week: Key Information to Consider
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify promising stocks based on price trends and earnings estimate revisions.
AtriCure's Performance: AtriCure (ATRC) currently holds a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The stock has shown significant price increases, outperforming both its industry and the S&P 500 over various time frames.
Earnings Estimate Revisions: Over the past two months, AtriCure has seen positive earnings estimate revisions, with two estimates moving higher for the current year and four for the next fiscal year, indicating strong potential for future performance.
Investment Recommendations: AtriCure is highlighted as a promising stock for investors looking for momentum picks, alongside other top recommendations from Zacks Investment Research that have shown significant growth potential.
See More
AtriCure Shares Plunge After JPMorgan Downgrade
- Downgrade Impact: JPMorgan downgraded AtriCure from Overweight to Neutral, causing shares to plunge by 15% during mid-day trading on Wednesday, indicating market concerns about the company's future performance.
- Price Target Reduction: The brokerage lowered its price target for AtriCure from $48 to $36, reflecting a significant decrease in analysts' expectations for the company's profitability, which may undermine investor confidence.
- Increased Competitive Pressure: The announcement by Edwards Lifesciences to launch a surgical left atrial appendage closure product, which competes with AtriCure's AtriClip, intensifies market competition and poses a threat to AtriCure's market share.
- Changing Market Position: Edwards Lifesciences' leading position in the cardiac surgery market, particularly in surgical valve replacements, could weaken AtriCure's market position in its Open business, further impacting its long-term growth potential.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
DexCom Reports Q4 2025 Revenue of $1.26 Billion, Up 13%
- Revenue Growth: DexCom's preliminary Q4 2025 total revenue reached approximately $1.26 billion, reflecting a 13% year-over-year increase and surpassing the Zacks consensus estimate of $1.25 billion, indicating strong market performance.
- U.S. and International Performance: U.S. revenues were about $892 million, an 11% increase year-over-year, while international revenues rose 18% to around $368 million, demonstrating the effectiveness of the company's global expansion strategy.
- Gross and Operating Margins: The company estimates an adjusted gross profit margin of approximately 61% and an operating margin of 20-21% for 2025, with elevated manufacturing scrap rates impacting margins, yet operational leverage has helped achieve overall margin expansion.
- 2026 Outlook: DexCom projects total revenues for 2026 to be between $5.16 billion and $5.25 billion, representing an estimated growth of 11-13%, with expected gross margins improving to 63-64%, reflecting strong confidence in future growth and robust market demand.
See More
VentriPoint Diagnostics Secures $1 Million Funding to Propel AI Medical Imaging Growth
- Market Growth Potential: The AI medical imaging market is projected to grow at an annual rate of 25.8% through 2034, driving a shift in healthcare from traditional hardware to agile, software-defined intelligence, creating significant opportunities for companies like VentriPoint.
- Successful Funding: VentriPoint doubled its private placement from $500,000 to $1 million, with proceeds earmarked for critical commercialization activities and manufacturing scale-up, ensuring the company maintains a competitive edge in the rapidly evolving market.
- Strategic Partnership: VentriPoint is collaborating with Summit Sciences to develop advanced ROI models aimed at demonstrating the economic value of its technology to healthcare providers, thereby enhancing market competitiveness and driving customer adoption.
- Executive Appointment: VentriPoint appointed David Swetlow as CFO, bringing over 15 years of management experience in the medical technology sector, which is viewed as a key step in executing strategies to drive market adoption and revenue growth.
See More
AtriCure Inc (ATRC) Releases 2025 Product Pipeline Analysis Report
- Product Pipeline Overview: AtriCure Inc's newly released 2025 Product Pipeline Analysis report provides key insights into its major products and brands, enhancing decision-making capabilities in the competitive medical technology market.
- Technical Expertise: AtriCure specializes in developing and providing medical devices for cardiac surgeries, including the Isolator Synergy ablation system and AtriClip left atrial appendage exclusion system, addressing the needs of electrophysiologists and cardiothoracic surgeons.
- Market Coverage: The company operates in multiple countries including the US, Germany, France, the UK, Canada, and Australia, showcasing its extensive global footprint aimed at enhancing competitiveness in the cardiac medical device sector.
- Brand Diversity: AtriCure markets its products through various brands such as Coolrail, Flex-V, and Hybrid AF, which increases the diversity of its product portfolio and enhances customer choice and market penetration.
See More
AtriCure (ATRC) Sees a 6.32% Increase Over the Past Week: Key Information to Consider
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation of selling them at even higher prices. The Zacks Momentum Style Score helps investors identify promising stocks based on price trends and earnings estimate revisions.
AtriCure's Performance: AtriCure (ATRC) currently holds a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The stock has shown significant price increases, outperforming both its industry and the S&P 500 over various time frames.
Earnings Estimate Revisions: Over the past two months, AtriCure has seen positive earnings estimate revisions, with two estimates moving higher for the current year and four for the next fiscal year, indicating strong potential for future performance.
Investment Recommendations: AtriCure is highlighted as a promising stock for investors looking for momentum picks, alongside other top recommendations from Zacks Investment Research that have shown significant growth potential.
See More
